Article

How Biofilms and Amyloid May Help to Trigger Lupus

ACR2013: More familiar as a suspect in Alzheimer disease, amyloid proteins may trigger autoantibodies in lupus when introduced via infection, a mouse study suggests.

A bacterial amyloid with the endearing name of curli that forms part of microbial biofilms is implicated a possible cause of lupus in studies using a mouse model of the disease at Temple University. The link to human lupus is less than purely theoretical, say researchers in the abstract of their scheduled presentation at the American College of Rheumatology annual meeting, because humans are exposed to curli during urinary tract and gastrointestinal infections.

The controlled experiment exposed wild-type and lupus-prone NZBW F1 mice to either curli derived from Salmonella cultures or to phosphate-buffered saline, injected intraperitoneally three times a week for five weeks, and then watched for the development of autoantibodies. The team found that immune cells (bone marrow-derived dendritic cells, to be specific) responded strongly to the presence of curli, producing "large quantities" of the interleukins IL-6, IL-10, and IL-12. Dendritic cells from the lupus-prone mice overexpressed interferon-producing genes compared to wild type.

Curli synergizes with DNA in the creation of biofilms, and the lupus-prone mice produced high quantities of autoantibodies to chromatin and nucleic acid after the injections of curli.

The upshot: In lupus-susceptible humans, nucleic acid-containing bacterial amyloids ininfectious  biofilms may be an important environmental trigger for autoantibody reactions.

Related Videos
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
Considering Viral Infections in Patients With Rheumatic Disease With Leonard Calabrese, DO
Leonard H. Calabrese, DO, Professor of Medicine and Vice Chair, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
Alvin Wells, MD, PhD: Making Informed Treatment Decisions With New Testing Strategies
Alvin Wells, MD, PhD
Upcoming Research in PsA, AxSpa, with Philip Mease, MD
Philip Mease, MD, Clinical Professor, University of Washington School of Medicine and Director, Rheumatology Research, Swedish Medical Center
© 2024 MJH Life Sciences

All rights reserved.